CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
Dec. 31, 2022	Dec. 31, 2021
Payment of offering costs	$ 0	$ 248
GSK [Member]
common stock issued discount value	$ 1,300
Common Stock [Member] \| Pfizer Purchase Agreement [Member]
Payments of financing costs		200
Premium on issued of common stock		$ 12,500

The cash outflow for cost incurred directly with the issuance of an equity security.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585

Name:	us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration